Neuroendocrine Tumours (NENs): New Treatments, Daraxonrasib & Why Genomic Testing Matters

Daraxonrasib is a promising new KRAS-targeted therapy that has shown significant benefits in metastatic pancreatic adenocarcinoma. But what does this mean for people with neuroendocrine tumours (NETs) or neuroendocrine carcinomas (NECs)? This article explains the differences between these cancers, why tumour biology matters, and how genomic testing can help guide personalised treatment decisions.

Angela

Patient Ambassador

Angela became an Ambassador in 2026.

/* ---- merged from snippet 271: Moth clipping path ---- */ /* ---- merged from snippet 312: Fancy text ---- */